Insmed Inc INSM

NASDAQ US Biotechnology

$98.60 ▼ -2.85% ($-2.89)

⬇️ Below Yest. Low 📅 Earnings This Week

Open $101.25

Prev Close $101.49

Day Range $97.05 – $101.91

52W Range $90.39 – $212.75

Market Cap $21.37B

Beta 0.81

EPS (TTM) $-5.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-02-15
Shares Out.	216,750,000
Website	insmed.com/ ↗
Phone	19089779900
Employees	1,664
Revenue	$306.0M
Gross Profit	$258.5M
Net Income	-$163.6M
Free Cash Flow	-$903.3M
Total Assets	$2.08B
Total Liabilities	$1.37B
Equity	$704.9M

About Insmed Inc

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Insmed Inc is a publicly traded company under the ticker symbol INSM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.